Contact Us
T: (212) 363-7500
F: (212) 363-7171
Copyright ©2011 Levi & Korsinsky, LLP
New York
Washington, DC
| Hospira, Inc. |
| Hospira, Inc. (NYSE: HSP) shareholder litigation in connection with alleged securities fraud |
Levi & Korsinsky announces that a class action
lawsuit has been commenced in the United States
District Court for the Northern District of Illinois on
behalf of purchasers of Hospira, Inc. (“Hospira” or
the “Company”) (NYSE: HSP) common stock
between March 24, 2009 and October 17, 2011.
lawsuit has been commenced in the United States
District Court for the Northern District of Illinois on
behalf of purchasers of Hospira, Inc. (“Hospira” or
the “Company”) (NYSE: HSP) common stock
between March 24, 2009 and October 17, 2011.
The complaint alleges that throughout the Class Period, defendants issued materially false and
misleading statements regarding the Company’s business and financial results. Specifically,
defendants failed to disclose that: (a) the Company suffered from extensive quality control issues
which undermined both the viability of and the supposed financial savings that would be generated
by Project Fuel, a Company program designed to optimize the Company’s operations and increase
shareholder value; (b) the Company was unable to remedy problems identified in FDA Warning
Letters related to Hospira’s infusion pumps, quality control deficiencies, and manufacturing
weaknesses; (c) Hospira misstated and lacked a reasonable basis for its revenue guidance for 2010
and 2011; and (d) as a result of the foregoing, defendants’ statements regarding the Company’s
financial performance and expected earnings were false and misleading.
In reaction to the Company’s negative results, on October 18, 2011 Hospira common stock fell
$7.85 per share to close at $29.51 per share.
If you suffered a loss in Hospira stock you have until January 20, 2012 to request that the Court
appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as
a lead plaintiff.
misleading statements regarding the Company’s business and financial results. Specifically,
defendants failed to disclose that: (a) the Company suffered from extensive quality control issues
which undermined both the viability of and the supposed financial savings that would be generated
by Project Fuel, a Company program designed to optimize the Company’s operations and increase
shareholder value; (b) the Company was unable to remedy problems identified in FDA Warning
Letters related to Hospira’s infusion pumps, quality control deficiencies, and manufacturing
weaknesses; (c) Hospira misstated and lacked a reasonable basis for its revenue guidance for 2010
and 2011; and (d) as a result of the foregoing, defendants’ statements regarding the Company’s
financial performance and expected earnings were false and misleading.
In reaction to the Company’s negative results, on October 18, 2011 Hospira common stock fell
$7.85 per share to close at $29.51 per share.
If you suffered a loss in Hospira stock you have until January 20, 2012 to request that the Court
appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as
a lead plaintiff.
